MAOB: Amine oxidase [flavin-containing] B
Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues.
- Drugs that act on it: 4
- Approved: 3
- In phases 1 to 3: 1
- Sponsors: 4
Who is on it, and how far along
Every drug ChEMBL records acting on MAOB, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 4
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- MDD US125%
- Newron Pharmaceuticals SPA125%
- Somerset Therapeutics125%
- Teva Pharmaceutical Industries125%
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Monoamine oxidase B inhibitor.| Safinamide | Approved | MDD US | Small molecule | Inhibitor | 2 |
| Rasagiline | Approved | Teva Pharmaceutical Industries | Small molecule | Inhibitor | 1 |
| SelegilineBoxed warning | Approved | Somerset Therapeutics | Small molecule | Inhibitor | 0 |
| Ralfinamide | Phase 3 | Newron Pharmaceuticals SPA | Small molecule | Inhibitor | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.| Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fluctuations | Safinamide | Phase 3 | Recruiting | Universita di Verona | Aug 13, 2026 |
| Fall Risk Assessment in Parkinson's Disease Using Kinetikos Health | Safinamide | — | Not yet recruiting | Taipei Medical University Shuang Ho Hospital | Dec 2, 2025 |
| Relative Bioavailability Study of HNC364 Injectable Suspension | Rasagiline | Phase 1 | Active, not recruiting | Guangzhou Henovcom Bioscience Co. Ltd. | Jan 29, 2025 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Parkinson disease
- 0.63
- Hypertensive disorder
- 0.47
- Melancholia
- 0.37
- Neurodegenerative disease
- 0.31
- Cocaine dependence
- 0.29
- Neuropathic pain
- 0.28
- Postural instability
- 0.26
Genes and related targets
Complexes and families that share a gene with this target- Genes
- MAOB
- Related
- Monoamine oxidase
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2039, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P27338, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets